MX9601150A - Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del erojecimiento cutaneo de origen neurogenico y composicion obtenida. - Google Patents

Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del erojecimiento cutaneo de origen neurogenico y composicion obtenida.

Info

Publication number
MX9601150A
MX9601150A MX9601150A MX9601150A MX9601150A MX 9601150 A MX9601150 A MX 9601150A MX 9601150 A MX9601150 A MX 9601150A MX 9601150 A MX9601150 A MX 9601150A MX 9601150 A MX9601150 A MX 9601150A
Authority
MX
Mexico
Prior art keywords
treatment
reddening
derived peptide
composition obtained
obtained therefrom
Prior art date
Application number
MX9601150A
Other languages
English (en)
Inventor
Olivier De Lacharriere
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477498&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9601150(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Publication of MX9601150A publication Critical patent/MX9601150A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere al uso de un antagonista de CGRP (péptido derivado del gen de calcitonina) en una composicion cosmética, farmacéutica o dermatologica, en particular para la aplicacion topica, para el tratamiento de enrojecimiento cutáneo de origen neurogénico, y en particular de rosácea y eritema discreto.
MX9601150A 1995-03-28 1996-03-27 Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del erojecimiento cutaneo de origen neurogenico y composicion obtenida. MX9601150A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503628A FR2732221B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue

Publications (1)

Publication Number Publication Date
MX9601150A true MX9601150A (es) 1997-02-28

Family

ID=9477498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9601150A MX9601150A (es) 1995-03-28 1996-03-27 Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del erojecimiento cutaneo de origen neurogenico y composicion obtenida.

Country Status (15)

Country Link
US (2) US5932215A (es)
EP (1) EP0734729B2 (es)
JP (1) JPH08268874A (es)
AR (1) AR002974A1 (es)
AT (1) ATE168011T1 (es)
BR (1) BR9601478A (es)
CA (1) CA2172777C (es)
DE (1) DE69600399T3 (es)
DK (1) DK0734729T4 (es)
ES (1) ES2121461T5 (es)
FR (1) FR2732221B1 (es)
HU (1) HUP9600765A3 (es)
MX (1) MX9601150A (es)
PL (1) PL313515A1 (es)
RU (1) RU2152798C1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
WO2002089743A2 (en) * 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
ES2323170T3 (es) 2002-08-12 2009-07-08 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para el tratamiento de la psoriasis.
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
JP5123197B2 (ja) 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
CA2727710C (en) * 2008-06-11 2016-11-01 Biochemics, Inc. Control of blood vessel physiology to treat skin disorders
CA2726726A1 (en) 2008-09-10 2010-03-18 Thrubit B.V. Ibuprofen for topical administration
WO2010034019A1 (en) * 2008-09-22 2010-03-25 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
EP2352543B1 (en) 2008-12-04 2019-04-03 BioChemics, Inc. Methods and compositions for tattoo removal
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP2470207A1 (en) 2009-08-28 2012-07-04 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
JP2013521300A (ja) 2010-03-03 2013-06-10 ネオキュティス エスアー 抗菌ペプチド隔離化合物を用いた皮膚疾患および皮膚障害の処置のための組成物および方法
BR112012024289A2 (pt) 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
CN103702685B (zh) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
PL2710039T3 (pl) 2011-05-20 2019-07-31 Alderbio Holdings Llc Kompozycje przeciwko CGRP i ich zastosowanie
CN111973740A (zh) 2014-03-21 2020-11-24 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
FR3030521B1 (fr) 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
US20180185360A1 (en) * 2015-06-29 2018-07-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
SG10201913032TA (en) 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
TW263498B (es) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
DE69523745T2 (de) * 1994-03-21 2002-08-08 Thomsen John Brown Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut
DE69529043T2 (de) * 1994-09-30 2003-05-08 Oreal Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728265A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
PL313515A1 (en) 1996-09-30
EP0734729B1 (fr) 1998-07-08
HU9600765D0 (en) 1996-05-28
US5932215A (en) 1999-08-03
EP0734729A1 (fr) 1996-10-02
EP0734729B2 (fr) 2004-09-29
CA2172777C (fr) 2007-07-24
JPH08268874A (ja) 1996-10-15
FR2732221A1 (fr) 1996-10-04
AR002974A1 (es) 1998-05-27
RU2152798C1 (ru) 2000-07-20
US6509014B1 (en) 2003-01-21
ES2121461T3 (es) 1998-11-16
DE69600399T2 (de) 1998-10-29
DK0734729T3 (da) 1999-04-19
ATE168011T1 (de) 1998-07-15
HUP9600765A2 (en) 1997-06-30
BR9601478A (pt) 1998-06-02
HUP9600765A3 (en) 1998-04-28
DK0734729T4 (da) 2004-10-25
FR2732221B1 (fr) 1997-04-25
DE69600399T3 (de) 2005-07-14
DE69600399D1 (de) 1998-08-13
ES2121461T5 (es) 2005-05-01
CA2172777A1 (fr) 1996-09-29

Similar Documents

Publication Publication Date Title
MX9601150A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del erojecimiento cutaneo de origen neurogenico y composicion obtenida.
CY2439B1 (en) Alpha-TNF antagonists in a cosmetic, pharmaceutical or dermotological composition.
AU3368497A (en) Human dnase i hyperactive variants
GB0309765D0 (en) A cosmetic or dermopharmaceutical composition comprising an enzyme which is insoluble in an aqueous medium, as well as its uses.
HUP0001293A1 (hu) Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására
PL312481A1 (en) Application of cgrp antagonist in cosmetic, pharmaceutical or dermatological composition and so obtained composition as such
NO952744D0 (no) Cytokinbegrensende midler
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
EP0393445A3 (de) Verwendung von renininhibitorischen Peptiden als Mittel gegen Retroviren
TR199802423T2 (xx) Konsantre antikor terkibi.
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
BR0000214A (pt) Loção capilar com propriedades melhoradas em sua ação protetora do cabelo e preventiva de sua queda e de redução dos efeitos externos da alopecia androgenética e com isso da queda do cabelo
ZA951974B (en) Bradykinin antagonist peptides incorporating N-subsituted glycines
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
GR3036184T3 (en) Heterocyclic diaryl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
MXPA02002117A (es) Uso de productos leguminosos para el tratamiento de agresiones externas.
MX9601151A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento de liquenes y prurito y composicion obtenida.
MX9505192A (es) Utilizacion de un antagonista de la substancia p para la obtencion de composiciones farmaceuticas para el tratamiento del enrojecimiento cutaneo de origen neurogenico.
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
AU2003292326A1 (en) Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme